RTEF-1 attenuates blood glucose levels by regulating insulin-like growth factor binding protein-1 in the endothelium

Circulation Research

Volumn 111, Issue 8, 2012, Pages 991-1001

  Messmer Blust, Angela F ^a   Philbrick, Melissa J ^a   Guo, Shuzhen ^b   Wu, Jiaping ^a   He, Ping ^c   Guo, Shaodong ^a   Li, Jian ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

IGFBP; metabolic syndrome; RTEF 1; vascular endothelium

Indexed keywords

GLUCOSE; INSULIN; MESSENGER RNA; RELATED TRANSCRIPTIONAL ENHANCER FACTOR 1; SOMATOMEDIN BINDING PROTEIN 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL FUNCTION; CELL METABOLISM; CONTROLLED STUDY; ENDOTHELIUM; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; GLUCOSE INTOLERANCE; HEARING; HEK293 CELLS; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MICE; MICE, KNOCKOUT; MUSCLE PROTEINS; OBESITY; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 84866944897     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.268110     Document Type: Article

References (48)

1. Jin Y, Wu J, Song X, Song Q, Cully BL, Messmer-Blust A, Xu M, Foo SY, Rosenzweig A, Li J. RTEF-1, an upstream gene of HIF-1α, accelerates recovery from ischemia. J Biol Chem. 2011;286:22699-22705.
2. Shie JL, Wu G, Wu J, Liu FF, Laham RJ, Oettgen P, Li J. RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol Chem. 2004;279:25010-25016. (Pubitemid 38756749)
3. Xu M, Jin Y, Song Q, Wu J, Philbrick MJ, Cully BL, An X, Guo L, Gao F, Li J. The endothelium-dependent effect of RTEF-1 in pressure overload cardiac hypertrophy: role of VEGF-B. Cardiovasc Res. 2011;90:325-334.
4. Messmer-Blust AF, Zhang C, Shie JL, Song Q, He P, Lubenec I, Liu Y, Sellke F, Li J. Related transcriptional enhancer factor 1 increases endothelial-dependent microvascular relaxation and proliferation. J Vasc Res. 2012;49:249-259.
5. Azakie A, Larkin SB, Farrance IK, Grenningloh G, Ordahl CP. DTEF-1, a novel member of the transcription enhancer factor-1 (TEF-1) multigene family. J Biol Chem. 1996;271:8260-8265. (Pubitemid 26108658)
6. Gan Q, Yoshida T, Li J, Owens GK. Smooth muscle cells and myofibroblasts use distinct transcriptional mechanisms for smooth muscle alpha-actin expression. Circ Res. 2007;101:883-892. (Pubitemid 350287175)
7. Maeda T, Gupta MP, Stewart AF. TEF-1 and MEF2 transcription factors interact to regulate muscle-specific promoters. Biochem Biophys Res Commun. 2002;294:791-797. (Pubitemid 34687186)
8. Anbanandam A, Albarado DC, Nguyen CT, Halder G, Gao X, Veeraraghavan S. Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain. Proc Natl Acad Sci USA. 2006;103:17225-17230. (Pubitemid 44788951)
9. Farrance IK, Mar JH, Ordahl CP. M-CAT binding factor is related to the SV40 enhancer binding factor, TEF-1. J Biol Chem. 1992;267:17234-17240.
10. Yagi R, Kohn MJ, Karavanova I, Kaneko KJ, Vullhorst D, DePamphilis ML, Buonanno A. Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development. Development. 2007;134:3827-3836. (Pubitemid 350187342)
11. Rodgers BD, Roalson EH, Thompson C. Phylogenetic analysis of the insulin-like growth factor binding protein (IGFBP) and IGFBP-related protein gene families. Gen Comp Endocrinol. 2008;155:201-207. (Pubitemid 350122486)
12. Ruan W, Lai M. Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol. 2010;47:5-14.
13. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824-854. (Pubitemid 35454590)
14. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res. 2000;86:125-130. (Pubitemid 30086171)
15. Delafontaine P, Ku L, Anwar A, Hayzer DJ. Insulin-like growth factor 1 binding protein 3 synthesis by aortic endothelial cells is a function of cell density. Biochem Biophys Res Commun. 1996;222:478-482. (Pubitemid 26335041)
16. Holly JM, Biddlecombe RA, Dunger DB, Edge JA, Amiel SA, Howell R, Chard T, Rees LH, Wass JA. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin: a new role for insulin? Clin Endocrinol (Oxf). 1988;29:667-675. (Pubitemid 19005514)
17. Snyder DK, Clemmons DR. Insulin-dependent regulation of insulin-like growth factor-binding protein-1. J Clin Endocrinol Metab. 1990;71:1632-1636. (Pubitemid 120032786)
18. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, Gibson JM. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001;44:333-339. (Pubitemid 32234460)
19. Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2008;18:166-173. (Pubitemid 351292519)
20. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004;89:114-120. (Pubitemid 38183869)
21. Kisanuki YY, Hammer RE, Miyazaki J, Williams SC, Richardson JA, Yanagisawa M. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230:230-242. (Pubitemid 32171420)
22. Gory S, Vernet M, Laurent M, Dejana E, Dalmon J, Huber P. The vascular endothelial-cadherin promoter directs endothelial-specific expression in transgenic mice. Blood. 1999;93:184-192. (Pubitemid 29019402)
23. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63. (Pubitemid 30022895)
24. Chen Z, Friedrich GA, Soriano P. Transcriptional enhancer factor 1 disruption by a retroviral gene trap leads to heart defects and embryonic lethality in mice. Genes Dev. 1994;8:2293-2301. (Pubitemid 24314291)
25. Lovejoy JC. The influence of dietary fat on insulin resistance. Curr Diab Rep. 2002;2:435-440.
26. Kim JJ, Taylor HS, Akbas GE, Foucher I, Trembleau A, Jaffe RC, Fazleabas AT, Unterman TG. Regulation of insulin-like growth factor binding protein-1 promoter activity by FKHR and HOXA10 in primate endometrial cells. Biol Reprod. 2003;68:24-30. (Pubitemid 36076314)
27. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274:17179-17183.
28. Foucher I, Volovitch M, Frain M, Kim JJ, Souberbielle JC, Gan L, Unterman TG, Prochiantz A, Trembleau A. Hoxa5 overexpression correlates with IGFBP1 upregulation and postnatal dwarfism: evidence for an interaction between Hoxa5 and Forkhead box transcription factors. Development. 2002;129:4065-4074. (Pubitemid 35012492)
29. Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A, Gibson JM. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes. Diabetes. 2002;51:2629-2636. (Pubitemid 34827416)
30. Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS, Taskinen MR. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care. 2002;25:1807-1812. (Pubitemid 41071091)
31. Alderete TL, Byrd-Williams CE, Toledo-Corral CM, Conti DV, Weigensberg MJ, Goran MI. Relationships between IGF-1 and IGFBP-1 and adiposity in obese African-American and Latino adolescents. Obesity (Silver Spring). 2010;19:933-938.
32. Gokulakrishnan K, Velmurugan K, Ganesan S, Mohan V. Circulating levels of insulin-like growth factor binding protein-1 in relation to insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (Chennai Urban Rural Epidemiology Study 118). Metabolism. 2012;61:43-46.
33. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia. 2008;51:1135-1145.
34. Petersson U, Ostgren CJ, Brudin L, Brismar K, Nilsson PM. Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the S̈oder?akra Cardiovascular Risk Factor Study. Diabetes Metab. 2009;35:198-205.
35. Reinehr T, Kleber M, Toschke AM, Woelfle J, Roth CL. Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int J Pediatr Obes. 2011;6:236-243.
36. Guilherme A, Torres K, Czech MP. Cross-talk between insulin receptor and integrin alpha5 beta1 signaling pathways. J Biol Chem. 1998;273:22899-22903. (Pubitemid 28417463)
37. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993;90:10553-10557. (Pubitemid 23347080)
38. Crossey PA, Jones JS, Miell JP. Dysregulation of the insulin/IGF binding protein-1 axis in transgenic mice is associated with hyperinsulinemia and glucose intolerance. Diabetes. 2000;49:457-465. (Pubitemid 30131793)
39. Wolf E, Schneider MR, Zhou R, Fisch TM, Herbach N, Dahlhoff M, Wanke R, Hoeflich A. Functional consequences of IGFBP excess: lessons from transgenic mice. Pediatr Nephrol. 2005;20:269-278. (Pubitemid 40309929)
40. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and-2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20:153-162.
41. Schlaeger TM, Qin Y, Fujiwara Y, Magram J, Sato TN. Vascular endothelial cell lineage-specific promoter in transgenic mice. Development. 1995;121:1089-1098.
42. Bastian SE, Walton PE, Belford DA. Paracellular transport of insulin-like growth factor-I (IGF-I) across human umbilical vein endothelial cell monolayers. J Cell Physiol. 1997;170:290-298. (Pubitemid 27117913)
43. Giannini S, Cresci B, Manuelli C, Fujita-Yamaguchi Y, Romagnani P, Mohan S, Rotella CM. Insulin-like growth factor binding protein production in bovine retinal endothelial cells. Metabolism. 1997;46:1367-1379. (Pubitemid 28053199)
44. Moser DR, Lowe WL Jr, Dake BL, Booth BA, Boes M, Clemmons DR, Bar RS. Endothelial cells express insulin-like growth factor-binding proteins 2 to 6. Mol Endocrinol. 1992;6:1805-1814.
45. Tucci M, Nygard K, Tanswell BV, Farber HW, Hill DJ, Han VK. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. J Endocrinol. 1998;157:13-24. (Pubitemid 28177488)
46. Worthmann K, Peters I, Kumpers P, Saleem M, Becker JU, Agustian PA, Achenbach J, Haller H, Schiffer M. Urinary excretion of IGFBP-1 and-3 correlates with disease activity and differentiates focal segmental glomerulosclerosis and minimal change disease. Growth Factors. 2010;28:129-138.
47. Shaw LC, Grant MB. Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord. 2004;5:199-207. (Pubitemid 38903577)
48. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171-176. (Pubitemid 30483118)